UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||||||||
(801 ) 727-1000
(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On March 21, 2023, HealthEquity, Inc. issued a press release attached as Exhibit 99.1 to this current report on Form 8-K.
The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | ||||
| 99.1 | |||||
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HEALTHEQUITY, INC. | |||||||||||
| Date: March 21, 2023 | By: | /s/ Tyson Murdock | |||||||||
| Name: | Tyson Murdock | ||||||||||
| Title: | Executive Vice President and Chief Financial Officer | ||||||||||
HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2023 Financial Results
Highlights of the fiscal year include:
•Revenue of $861.7 million, an increase of 14% compared to $756.6 million in FY22.
•Net loss of $26.1 million, compared to $44.3 million in FY22, with non-GAAP net income of $114.5 million, compared to $110.2 million in FY22.
•Net loss per diluted share of $0.31, compared to $0.53 in FY22, with non-GAAP net income per diluted share of $1.36, compared to $1.33 in FY22.
•Adjusted EBITDA of $272.3 million, an increase of 15% compared to $236.0 million in FY22.
•8.0 million HSAs, an increase of 11% compared to FY22.
•Total HSA Assets of $22.1 billion, an increase of 13% compared to FY22.
•14.9 million Total Accounts, including both HSAs and complementary CDBs, an increase of 4% compared to FY22.
Highlights of the fourth quarter include:
•Revenue of $233.8 million, an increase of 15% compared to $203.3 million in Q4 FY22.
•Net loss of $0.2 million, compared to $32.8 million in Q4 FY22, with non-GAAP net income of $31.3 million, compared to $17.0 million in Q4 FY22.
•Net loss per diluted share of less than one cent, compared to $0.39 in Q4 FY22, with non-GAAP net income per diluted share of $0.37, compared to $0.20 in Q4 FY22.
•Adjusted EBITDA of $73.6 million, an increase of 46% compared to $50.4 million in Q4 FY22.
Draper, Utah – March 21, 2023 – HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced financial results for its fourth quarter and fiscal year ended January 31, 2023.
“Team Purple closed out fiscal 2023 in record fashion with its best year of new HSAs from sales, its highest ever HSAs, HSA Assets, and Total Accounts, and record revenue and Adjusted EBITDA,” said Jon Kessler, HealthEquity President and CEO. “In fiscal 2023, HealthEquity became the largest HSA custodian measured by both accounts and HSA Assets. In fiscal 2024, we believe we are strongly positioned to continue to outpace overall market growth, substantially improve profit margins, and execute on our vision to help our members more fully connect health and wealth.”
Fiscal year financial results
Revenue for the fiscal year ended January 31, 2023 was $861.7 million, an increase of 14% compared to $756.6 million for the fiscal year ended January 31, 2022. Revenue this year included: service revenue of $430.2 million, custodial revenue of $283.1 million, and interchange revenue of $148.4 million.
HealthEquity reported a net loss of $26.1 million, or $0.31 per diluted share, and non-GAAP net income of $114.5 million, or $1.36 per diluted share, for the fiscal year ended January 31, 2023. The Company reported a net loss of $44.3 million, or $0.53 per diluted share, and non-GAAP net income of $110.2 million, or $1.33 per diluted share, for the fiscal year ended January 31, 2022.
Adjusted EBITDA was $272.3 million for the fiscal year ended January 31, 2023, an increase of 15% compared to $236.0 million for the fiscal year ended January 31, 2022. Adjusted EBITDA was 32% of revenue, compared to 31% for the fiscal year ended January 31, 2022.
As of January 31, 2023, HealthEquity had $254.3 million of cash and cash equivalents and $925.3 million of outstanding debt, net of issuance costs. This compares to $225.4 million in cash and cash equivalents and $930.8 million of outstanding debt as of January 31, 2022.
Fourth quarter financial results
Revenue for the fourth quarter ended January 31, 2023 was $233.8 million, an increase of 15% compared to $203.3 million for the fourth quarter ended January 31, 2022. Revenue this quarter included: service revenue of $114.2 million, custodial revenue of $83.5 million, and interchange revenue of $36.1 million.
HealthEquity reported a net loss of $0.2 million, or less than one cent per diluted share, and non-GAAP net income of $31.3 million, or $0.37 per diluted share, for the fourth quarter ended January 31, 2023. The Company reported a net
1
loss of $32.8 million, or $0.39 per diluted share, and non-GAAP net income of $17.0 million, or $0.20 per diluted share, for the fourth quarter ended January 31, 2022.
Adjusted EBITDA was $73.6 million for the fourth quarter ended January 31, 2023, an increase of 46% compared to $50.4 million for the fourth quarter ended January 31, 2022. Adjusted EBITDA was 31% of revenue, compared to 25% for the fourth quarter ended January 31, 2022.
Account and asset metrics
HSAs as of January 31, 2023 were approximately 8.0 million, an increase of 11% year over year, including 541,000 HSAs with investments, an increase of 19% year over year. Total Accounts as of January 31, 2023 were 14.9 million, including 6.9 million other consumer-directed benefits ("CDBs").
Total HSA Assets as of January 31, 2023 were $22.1 billion, an increase of 13% year over year. Total HSA Assets included $14.2 billion of HSA cash and $7.9 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.9 billion as of January 31, 2023.
Business outlook
For the fiscal year ending January 31, 2024, management expects revenues of $960 million to $975 million. Its outlook for net income is between $0 and $11 million, resulting in net income of $0.00 to $0.13 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $152 million and $163 million, resulting in non-GAAP net income per diluted share of $1.74 to $1.87 (based on an estimated 87 million weighted-average shares outstanding). Management expects Adjusted EBITDA of $320 million to $335 million.
See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.
Conference call
HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, March 21, 2023 to discuss the fiscal 2023 fourth quarter and year-end results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity, Inc. call." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.
Non-GAAP financial information
To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.
•Adjusted EBITDA is adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
•Non-GAAP net income is calculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
•Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.
Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of
2
the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for our more than 14 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
•our dependence on the continued availability and benefits of tax-advantaged health savings accounts and other consumer-directed benefits;
•our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
•our ability to realize the anticipated financial and other benefits from combining the operations of recent and future acquisitions with our business successfully;
•our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
•our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
•the significant competition we face and may face in the future, including from those with greater resources than us;
•the impact of societal and economic changes arising out of the COVID-19 pandemic on the Company, its operations and its financial results;
•our reliance on the availability and performance of our technology and communications systems;
•potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
•the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
•our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
•our reliance on partners and third-party vendors for distribution and important services;
•our ability to develop and implement updated features for our technology and communications systems and successfully manage our growth;
•our ability to protect our brand and other intellectual property rights; and
•our reliance on our management team and key team members.
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our most recent Annual Report on Form 10-K and
3
subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations Contact
Richard Putnam
801-727-1209
rputnam@healthequity.com
4
HealthEquity, Inc. and subsidiaries
Consolidated balance sheets (unaudited)
| (in thousands, except par value) | January 31, 2023 | January 31, 2022 | |||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 254,266 | $ | 225,414 | |||||||
| Accounts receivable, net of allowance for doubtful accounts of $4,989 and $6,228 as of January 31, 2023 and 2022, respectively | 96,835 | 87,428 | |||||||||
| Other current assets | 31,792 | 38,495 | |||||||||
| Total current assets | 382,893 | 351,337 | |||||||||
| Property and equipment, net | 12,862 | 23,372 | |||||||||
| Operating lease right-of-use assets | 56,461 | 63,613 | |||||||||
| Intangible assets, net | 936,359 | 973,137 | |||||||||
| Goodwill | 1,648,145 | 1,645,836 | |||||||||
| Other assets | 52,180 | 49,807 | |||||||||
| Total assets | $ | 3,088,900 | $ | 3,107,102 | |||||||
| Liabilities and stockholders’ equity | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable | $ | 13,899 | $ | 27,541 | |||||||
| Accrued compensation | 45,835 | 47,136 | |||||||||
| Accrued liabilities | 43,668 | 57,589 | |||||||||
| Current portion of long-term debt | 17,500 | 8,750 | |||||||||
| Operating lease liabilities | 10,159 | 12,171 | |||||||||
| Total current liabilities | 131,061 | 153,187 | |||||||||
| Long-term liabilities | |||||||||||
| Long-term debt, net of issuance costs | 907,838 | 922,077 | |||||||||
| Operating lease liabilities, non-current | 58,988 | 65,232 | |||||||||
| Other long-term liabilities | 12,708 | 14,185 | |||||||||
| Deferred tax liability | 82,665 | 99,846 | |||||||||
| Total long-term liabilities | 1,062,199 | 1,101,340 | |||||||||
| Total liabilities | 1,193,260 | 1,254,527 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity | |||||||||||
| Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of January 31, 2023 and 2022 | — | — | |||||||||
| Common stock, $0.0001 par value, 900,000 shares authorized, 84,758 and 83,780 shares issued and outstanding as of January 31, 2023 and 2022, respectively | 8 | 8 | |||||||||
| Additional paid-in capital | 1,745,716 | 1,676,508 | |||||||||
| Accumulated earnings | 149,916 | 176,059 | |||||||||
| Total stockholders’ equity | 1,895,640 | 1,852,575 | |||||||||
| Total liabilities and stockholders’ equity | $ | 3,088,900 | $ | 3,107,102 | |||||||
5
HealthEquity, Inc. and subsidiaries
Consolidated statements of operations and comprehensive loss (unaudited)
| Three months ended January 31, | Year ended January 31, | ||||||||||||||||||||||
| (in thousands, except per share data) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Service revenue | $ | 114,234 | $ | 112,461 | $ | 430,196 | $ | 426,910 | |||||||||||||||
| Custodial revenue | 83,506 | 58,057 | 283,112 | 202,817 | |||||||||||||||||||
| Interchange revenue | 36,101 | 32,779 | 148,440 | 126,829 | |||||||||||||||||||
| Total revenue | 233,841 | 203,297 | 861,748 | 756,556 | |||||||||||||||||||
| Cost of revenue | |||||||||||||||||||||||
| Service costs | 85,079 | 86,119 | 317,360 | 290,302 | |||||||||||||||||||
| Custodial costs | 8,558 | 6,300 | 29,101 | 21,867 | |||||||||||||||||||
| Interchange costs | 5,956 | 5,579 | 25,196 | 20,681 | |||||||||||||||||||
| Total cost of revenue | 99,593 | 97,998 | 371,657 | 332,850 | |||||||||||||||||||
| Gross profit | 134,248 | 105,299 | 490,091 | 423,706 | |||||||||||||||||||
| Operating expenses | |||||||||||||||||||||||
| Sales and marketing | 19,201 | 16,317 | 68,849 | 58,605 | |||||||||||||||||||
| Technology and development | 52,722 | 45,927 | 193,375 | 157,364 | |||||||||||||||||||
| General and administrative | 20,833 | 20,876 | 95,628 | 84,379 | |||||||||||||||||||
| Amortization of acquired intangible assets | 23,166 | 23,046 | 94,586 | 82,791 | |||||||||||||||||||
| Merger integration | 5,110 | 26,383 | 28,596 | 64,805 | |||||||||||||||||||
| Total operating expenses | 121,032 | 132,549 | 481,034 | 447,944 | |||||||||||||||||||
| Income (loss) from operations | 13,216 | (27,250) | 9,057 | (24,238) | |||||||||||||||||||
| Other expense | |||||||||||||||||||||||
| Interest expense | (14,305) | (10,748) | (48,424) | (36,572) | |||||||||||||||||||
| Other income (expense), net | 1,097 | (5,767) | 1,271 | (5,931) | |||||||||||||||||||
| Total other expense | (13,208) | (16,515) | (47,153) | (42,503) | |||||||||||||||||||
| Income (loss) before income taxes | 8 | (43,765) | (38,096) | (66,741) | |||||||||||||||||||
| Income tax provision (benefit) | 217 | (10,947) | (11,953) | (22,452) | |||||||||||||||||||
| Net loss and comprehensive loss | $ | (209) | $ | (32,818) | $ | (26,143) | $ | (44,289) | |||||||||||||||
| Net loss per share: | |||||||||||||||||||||||
| Basic | $ | 0.00 | $ | (0.39) | $ | (0.31) | $ | (0.53) | |||||||||||||||
| Diluted | $ | 0.00 | $ | (0.39) | $ | (0.31) | $ | (0.53) | |||||||||||||||
| Weighted-average number of shares used in computing net loss per share: | |||||||||||||||||||||||
| Basic | 84,718 | 83,708 | 84,442 | 83,133 | |||||||||||||||||||
| Diluted | 84,718 | 83,708 | 84,442 | 83,133 | |||||||||||||||||||
6
HealthEquity, Inc. and subsidiaries
Consolidated statements of cash flows (unaudited)
| Year ended January 31, | |||||||||||||||||
| (in thousands) | 2023 | 2022 | 2021 | ||||||||||||||
| Cash flows from operating activities: | |||||||||||||||||
| Net income (loss) | $ | (26,143) | $ | (44,289) | $ | 8,834 | |||||||||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||||||||||||
| Depreciation and amortization | 161,201 | 137,188 | 115,904 | ||||||||||||||
| Stock-based compensation | 62,614 | 52,750 | 42,863 | ||||||||||||||
| Impairment of right-of-use assets | — | 11,246 | — | ||||||||||||||
| Amortization of debt issuance costs | 3,261 | 4,448 | 5,102 | ||||||||||||||
| Loss on extinguishment of debt | — | 4,049 | — | ||||||||||||||
| Change in fair value of contingent consideration | — | (2,147) | — | ||||||||||||||
| Gains on equity securities | — | (1,677) | — | ||||||||||||||
| Other non-cash items | 268 | 1,232 | 1,753 | ||||||||||||||
| Deferred taxes | (17,181) | (23,430) | (5,132) | ||||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||||
| Accounts receivable | (9,570) | (11,204) | (413) | ||||||||||||||
| Other assets | 4,620 | 7,464 | (24,839) | ||||||||||||||
| Operating lease right-of-use assets | 8,244 | 15,235 | 11,150 | ||||||||||||||
| Accrued compensation | (1,282) | (3,657) | 771 | ||||||||||||||
| Accounts payable, accrued liabilities, and other current liabilities | (26,673) | (2,178) | 30,422 | ||||||||||||||
| Operating lease liabilities, non-current | (7,232) | (9,412) | (10,803) | ||||||||||||||
| Other long-term liabilities | (1,477) | 5,377 | 6,007 | ||||||||||||||
| Net cash provided by operating activities | 150,650 | 140,995 | 181,619 | ||||||||||||||
| Cash flows from investing activities: | |||||||||||||||||
| Business combinations, net of cash acquired | — | (504,533) | — | ||||||||||||||
| Purchases of software and capitalized software development costs | (45,173) | (62,708) | (51,500) | ||||||||||||||
| Acquisitions of HSA portfolios | (70,583) | (65,465) | (32,371) | ||||||||||||||
| Purchases of property and equipment | (3,371) | (8,908) | (13,093) | ||||||||||||||
| Proceeds from sale of equity securities | — | 2,367 | — | ||||||||||||||
| Net cash used in investing activities | (119,127) | (639,247) | (96,964) | ||||||||||||||
| Cash flows from financing activities: | |||||||||||||||||
| Principal payments on long-term debt | (8,750) | (1,003,125) | (239,063) | ||||||||||||||
| Proceeds from long-term debt | — | 950,000 | — | ||||||||||||||
| Payment of debt issuance costs | — | (11,920) | — | ||||||||||||||
| Proceeds from follow-on equity offering, net of payments for offering costs | — | 456,640 | 286,779 | ||||||||||||||
| Settlement of client-held funds obligation, net | (603) | (486) | (3,862) | ||||||||||||||
| Proceeds from exercise of common stock options | 6,682 | 9,754 | 8,568 | ||||||||||||||
| Payment of contingent consideration | — | (6,000) | — | ||||||||||||||
| Net cash provided by (used in) financing activities | (2,671) | 394,863 | 52,422 | ||||||||||||||
| Increase (decrease) in cash and cash equivalents | 28,852 | (103,389) | 137,077 | ||||||||||||||
| Beginning cash and cash equivalents | 225,414 | 328,803 | 191,726 | ||||||||||||||
| Ending cash and cash equivalents | $ | 254,266 | $ | 225,414 | $ | 328,803 | |||||||||||
7
HealthEquity, Inc. and subsidiaries
Consolidated statements of cash flows (unaudited) (continued)
| Year ended January 31, | |||||||||||||||||
| (in thousands) | 2023 | 2022 | 2021 | ||||||||||||||
| Supplemental cash flow data: | |||||||||||||||||
| Interest expense paid in cash | $ | 43,570 | $ | 16,107 | $ | 27,686 | |||||||||||
| Income tax payments (refunds), net | 1,526 | (5,632) | (6,022) | ||||||||||||||
| Supplemental disclosures of non-cash investing and financing activities: | |||||||||||||||||
| Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation | 3,595 | 4,640 | 1,930 | ||||||||||||||
| Purchases of property and equipment included in accounts payable or accrued liabilities | 69 | 1,414 | 160 | ||||||||||||||
| Acquisitions of HSA portfolios included in accounts payable or accrued liabilities | — | 1,692 | — | ||||||||||||||
| Decrease (increase) in goodwill due to measurement period adjustments, net | (2,309) | 19 | 5,438 | ||||||||||||||
| Exercise of common stock options receivable | 382 | 470 | 1,478 | ||||||||||||||
Stock-based compensation expense (unaudited)
Total stock-based compensation expense included in the consolidated statements of operations and comprehensive income (loss) is as follows:
| Three months ended January 31, | Year ended January 31, | ||||||||||||||||||||||
| (in thousands) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Cost of revenue | $ | 3,759 | $ | 2,711 | $ | 14,426 | $ | 11,258 | |||||||||||||||
| Sales and marketing | 2,685 | 1,324 | 9,821 | 7,001 | |||||||||||||||||||
| Technology and development | 3,440 | 2,968 | 13,828 | 13,132 | |||||||||||||||||||
| General and administrative | 2,420 | 4,047 | 24,539 | 21,359 | |||||||||||||||||||
| Other expense, net | — | — | — | 342 | |||||||||||||||||||
| Total stock-based compensation expense | $ | 12,304 | $ | 11,050 | $ | 62,614 | $ | 53,092 | |||||||||||||||
Total Accounts (unaudited)
| (in thousands, except percentages) | January 31, 2023 | January 31, 2022 | % Change | ||||||||||||||
| HSAs | 7,984 | 7,207 | 11 | % | |||||||||||||
| New HSAs from sales - Quarter-to-date | 445 | 472 | (6) | % | |||||||||||||
| New HSAs from sales - Year-to-date | 971 | 918 | 6 | % | |||||||||||||
| New HSAs from acquisitions - Year-to-date | 90 | 740 | (88) | % | |||||||||||||
| HSAs with investments | 541 | 455 | 19 | % | |||||||||||||
| CDBs | 6,933 | 7,192 | (4) | % | |||||||||||||
| Total Accounts | 14,917 | 14,399 | 4 | % | |||||||||||||
| Average Total Accounts - Quarter-to-date | 14,677 | 14,326 | 2 | % | |||||||||||||
| Average Total Accounts - Year-to-date | 14,531 | 13,450 | 8 | % | |||||||||||||
8
HSA assets (unaudited)
| (in millions, except percentages) | January 31, 2023 | January 31, 2022 | % Change | ||||||||||||||
| HSA cash | $ | 14,199 | $ | 12,943 | 10 | % | |||||||||||
| HSA investments | 7,947 | 6,675 | 19 | % | |||||||||||||
| Total HSA Assets | 22,146 | 19,618 | 13 | % | |||||||||||||
| Average daily HSA cash - Year-to-date | 13,049 | 10,579 | 23 | % | |||||||||||||
| Average daily HSA cash - Quarter-to-date | 13,375 | 12,118 | 10 | % | |||||||||||||
Client-held funds (unaudited)
| (in millions, except percentages) | January 31, 2023 | January 31, 2022 | % Change | ||||||||||||||
| Client-held funds | $ | 901 | $ | 897 | 0 | % | |||||||||||
| Average daily Client-held funds - Year-to-date | 827 | 842 | (2) | % | |||||||||||||
| Average daily Client-held funds - Quarter-to-date | 809 | 822 | (2) | % | |||||||||||||
Net loss reconciliation to Adjusted EBITDA (unaudited)
| Three months ended January 31, | Year ended January 31, | ||||||||||||||||||||||
| (in thousands) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Net loss | $ | (209) | $ | (32,818) | $ | (26,143) | $ | (44,289) | |||||||||||||||
| Interest income | (1,179) | (82) | (1,763) | (1,501) | |||||||||||||||||||
| Interest expense | 14,305 | 10,748 | 48,424 | 36,572 | |||||||||||||||||||
| Income tax provision (benefit) | 217 | (10,947) | (11,953) | (22,452) | |||||||||||||||||||
| Depreciation and amortization | 17,309 | 15,778 | 66,615 | 54,397 | |||||||||||||||||||
| Amortization of acquired intangible assets | 23,166 | 23,046 | 94,586 | 82,791 | |||||||||||||||||||
| Stock-based compensation expense | 12,304 | 11,050 | 62,614 | 52,750 | |||||||||||||||||||
| Merger integration expenses | 5,110 | 26,383 | 28,596 | 64,805 | |||||||||||||||||||
| Acquisition costs (1) | — | 5,915 | 53 | 10,832 | |||||||||||||||||||
| Gain on equity securities | — | (15) | — | (1,692) | |||||||||||||||||||
| Amortization of incremental costs to obtain a contract | 1,137 | 861 | 4,393 | 4,326 | |||||||||||||||||||
| Costs associated with unused office space | 1,170 | — | 4,958 | — | |||||||||||||||||||
| Other | 278 | 520 | 1,968 | (524) | |||||||||||||||||||
| Adjusted EBITDA | $ | 73,608 | $ | 50,439 | $ | 272,348 | $ | 236,015 | |||||||||||||||
(1)For the fiscal year ended January 31, 2022, acquisition costs included $0.3 million of stock-based compensation expense.
9
Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)
| Outlook for the year ending | |||||
| (in millions) | January 31, 2024 | ||||
| Net income | $0 - 11 | ||||
| Interest income | (7) | ||||
| Interest expense | 57 | ||||
| Income tax provision | 0 - 4 | ||||
| Depreciation and amortization | 61 | ||||
| Amortization of acquired intangible assets | 93 | ||||
| Stock-based compensation expense | 88 | ||||
| Merger integration expenses | 17 | ||||
| Amortization of incremental costs to obtain a contract | 5 | ||||
| Costs associated with unused office space | 4 | ||||
| Other expense | 2 | ||||
| Adjusted EBITDA | $320 - 335 | ||||
Reconciliation of net loss to non-GAAP net income (unaudited)
| Three months ended January 31, | Year ended January 31, | ||||||||||||||||||||||
| (in thousands, except per share data) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Net loss | $ | (209) | $ | (32,818) | $ | (26,143) | $ | (44,289) | |||||||||||||||
| Income tax provision (benefit) | 217 | (10,947) | (11,953) | (22,452) | |||||||||||||||||||
| Income (loss) before income taxes - GAAP | 8 | (43,765) | (38,096) | (66,741) | |||||||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||
| Amortization of acquired intangible assets | 23,166 | 23,046 | 94,586 | 82,791 | |||||||||||||||||||
| Stock-based compensation expense | 12,304 | 11,050 | 62,614 | 52,750 | |||||||||||||||||||
| Merger integration expenses | 5,110 | 26,383 | 28,596 | 64,805 | |||||||||||||||||||
| Acquisition costs | — | 5,915 | 53 | 10,832 | |||||||||||||||||||
| Gain on equity securities | — | (15) | — | (1,692) | |||||||||||||||||||
| Costs associated with unused office space | 1,170 | — | 4,958 | — | |||||||||||||||||||
| Loss on extinguishment of debt | — | — | — | 4,192 | |||||||||||||||||||
| Total adjustments to loss before income taxes - GAAP | 41,750 | 66,379 | 190,807 | 213,678 | |||||||||||||||||||
| Income before income taxes - Non-GAAP | 41,758 | 22,614 | 152,711 | 146,937 | |||||||||||||||||||
| Income tax provision - Non-GAAP (1) | 10,440 | 5,653 | 38,178 | 36,734 | |||||||||||||||||||
| Non-GAAP net income | 31,318 | 16,961 | 114,533 | 110,203 | |||||||||||||||||||
| Diluted weighted-average shares | 84,718 | 83,708 | 84,442 | 83,133 | |||||||||||||||||||
| Non-GAAP net income per diluted share | $ | 0.37 | $ | 0.20 | $ | 1.36 | $ | 1.33 | |||||||||||||||
(1)The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
10
Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)
| Outlook for the year ending | |||||
| (in millions, except per share data) | January 31, 2024 | ||||
| Net income | $0 - 11 | ||||
| Income tax provision | 0 - 4 | ||||
| Income before income taxes - GAAP | 0 - 15 | ||||
| Non-GAAP adjustments: | |||||
| Amortization of acquired intangible assets | 93 | ||||
| Stock-based compensation expense | 88 | ||||
| Merger integration expenses | 17 | ||||
| Costs associated with unused office space | 4 | ||||
| Total adjustments to income before income taxes - GAAP | 202 | ||||
| Income before income taxes - Non-GAAP | 202 - 217 | ||||
| Income tax provision - Non-GAAP (1) | 50 - 54 | ||||
| Non-GAAP net income | $152 - 163 | ||||
| Diluted weighted-average shares | 87 | ||||
| Non-GAAP net income per diluted share (2) | $1.74 - 1.87 | ||||
(1)The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
(2)Non-GAAP net income per diluted share may not calculate due to rounding of non-GAAP net income and diluted weighted-average shares.
Certain terms
| Term | Definition | ||||
| HSA | A financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis. | ||||
| CDB | Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits. | ||||
| HSA member | Consumers with HSAs that we serve. | ||||
| Total HSA Assets | HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments in mutual funds through our custodial investment fund partner. | ||||
| Client | Our employer clients. | ||||
| Total Accounts | The sum of HSAs and CDBs on our platforms. | ||||
| Client-held funds | Deposits held on behalf of our Clients to facilitate administration of our CDBs. | ||||
| Network Partner | Our health plan partners, benefits administrators, and retirement plan recordkeepers. | ||||
| Adjusted EBITDA | Adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items. | ||||
| Non-GAAP net income | Calculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate. | ||||
| Non-GAAP net income per diluted share | Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding. | ||||
11